FY2030 Earnings Forecast for ZNTL Issued By HC Wainwright

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Investment analysts at HC Wainwright issued their FY2030 EPS estimates for Zentalis Pharmaceuticals in a research note issued on Friday, March 27th. HC Wainwright analyst A. Maldonado expects that the company will post earnings of ($0.06) per share for the year. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share.

Other analysts have also issued research reports about the company. Wall Street Zen lowered Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. Wells Fargo & Company assumed coverage on Zentalis Pharmaceuticals in a report on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 target price on the stock. Finally, Guggenheim restated a “buy” rating and set a $6.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Zentalis Pharmaceuticals presently has an average rating of “Hold” and an average target price of $5.17.

Zentalis Pharmaceuticals Trading Up 1.9%

Shares of ZNTL opened at $2.14 on Monday. The firm has a fifty day simple moving average of $2.55 and a two-hundred day simple moving average of $1.95. The firm has a market cap of $151.79 million, a PE ratio of -1.13 and a beta of 1.71. Zentalis Pharmaceuticals has a 1-year low of $1.01 and a 1-year high of $3.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Thursday, March 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.08).

Insider Buying and Selling at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, major shareholder Group Walters acquired 6,459,973 shares of the business’s stock in a transaction dated Wednesday, December 31st. The stock was purchased at an average price of $1.20 per share, with a total value of $7,751,967.60. Following the transaction, the insider directly owned 13,509,973 shares in the company, valued at approximately $16,211,967.60. The trade was a 91.63% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Vincent Vultaggio sold 29,951 shares of the company’s stock in a transaction on Friday, February 6th. The stock was sold at an average price of $2.43, for a total value of $72,780.93. Following the completion of the sale, the insider owned 156,779 shares of the company’s stock, valued at $380,972.97. This trade represents a 16.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 46,617 shares of company stock worth $113,417 in the last quarter. Corporate insiders own 1.90% of the company’s stock.

Institutional Trading of Zentalis Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Sivia Capital Partners LLC purchased a new position in shares of Zentalis Pharmaceuticals during the 4th quarter valued at about $27,000. Qube Research & Technologies Ltd purchased a new stake in Zentalis Pharmaceuticals in the 2nd quarter worth approximately $37,000. Corient Private Wealth LLC purchased a new stake in Zentalis Pharmaceuticals in the 2nd quarter worth approximately $41,000. Voleon Capital Management LP bought a new stake in Zentalis Pharmaceuticals during the 3rd quarter worth approximately $41,000. Finally, SG Americas Securities LLC raised its stake in Zentalis Pharmaceuticals by 35.3% during the 3rd quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock worth $48,000 after acquiring an additional 8,236 shares during the period.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.